

ASX Release

SUDA EXPANDS BUSINESS DEVELOPMENT TEAM

PERTH, AUSTRALIA – 4 June 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has entered into success-based agreements with two international specialty consulting groups as part of its strategic expansion of its business development footprint in the USA, Europe, Russia and China.

Andrew Curtis has engaged an Illinois-based, boutique life sciences commercial services company. The company has been engaged to focus on the mid-tier US biotech and specialty pharmaceutical companies. The company's principal has over 30 years' experience working in leadership, commercial strategy development and tactical oversight with a large number of International and US-based pharmaceutical companies.

JEZANS, a Hong Kong based commercial services company serving the life science industry in China, Europe and Russia, will focus on mid-sized private and State-owned companies in the above territories. Zona Yim, the Chief Executive of JEZANS, has a long and successful track record in business development transactions throughout the territory.

Both companies will work on a success-based remuneration model.

SUDA's CEO Stephen Carter said that "We look forward to working with both companies in their areas of expertise and to leverage of their comprehensive industry networks to further enhance the business development success of SUDA."



Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA Pharmaceuticals Ltd
Tel: +61 8 6142 555
sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com